ACCESS TO QUALITY AFFORDABLE MEDICINES

CiplaQCi

CIPLA QUALITY CHEMICAL INDUSTRIES LTD: RESIGNATIONS FROM THE BOARD OF DIRECTORS

Uganda, Kampala 15th March 2019 – Cipla Quality Chemical Industries Ltd ("CiplaQCIL") hereby makes the following announcement:

The Board of Directors has accepted resignations of the following Non – Executive Directors effective 28th February, 2019; Ms. Beth Mandel, Mr. Zain Latif and Mr. Chandru Chawla. The Board is in the process of nominating Directors to represent institutional investors and will present them to the shareholders for final approval of their appointments at the next Annual General Meeting as shall be notified in due course. The Board of Directors and shareholders acknowledge and thank Beth, Zain and Chandru for their enormous contribution and invaluable efforts towards helping build this business over the last nine years and wish them the best in the years ahead.

About Cipla Quality Chemical Industries Ltd

CiplaQCIL is a state-of-the-art pharmaceutical plant based in Kampala, Uganda and focused on production of high quality WHO pre-qualified life-saving medicines for the SSA region. The company's products and pipeline target three major diseases that are widespread in Uganda and Sub Saharan Africa and comprise Anti-malarials, Anti-retrovirals and Hepatitis B and C drugs. CiplaQCIL has been approved by regulatory bodies across Africa including: Uganda, Kenya, Rwanda, Tanzania, Namibia, Ivory Coast, Zambia, Zimbabwe, Malawi, Namibia, Mozambique, Ghana, Ethiopia, Angola and South Sudan.

Emmanuel Katongole

Executive Chairman

NJ.Brooked

Nevin James Bradford Chief Executive Officer